Skip to content

Maya Renal Hypertension Ablation System Study

Low Level RF Renal Ablation in Chronic Hypertensive Patients to Treat Resistancy to Anti Hypertensive Medication By Lowering Systolic Blood Pressure

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12611000987965
Enrollment
9
Registered
2011-09-16
Start date
2011-11-02
Completion date
2012-03-07
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

An initial evaluation of the Maya Renal Hypertension Ablation System for the treatment of subjects with chronic resistant hypertension

Interventions

Balloon Catheter delivers low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney. The treatment time is approximately 2 minutes. Catheter is removed from the body at the end of procedure.

Sponsors

Maya Medical
Lead SponsorOther Collaborative groups

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Subject has a systolic blood pressure greater than or equal to 160 mmHg Subject is on 2 or more anti hypertensive medications Bilateral Renal Arteries must be between 4-7mm diameter and greater than 20mm in length Subject signs informed consent and agrees to follow up visits

Exclusion criteria

Subject has a glomerular filtration rate (eGFR) of < 45mL/min/1.73m2, using the MDRD calculation. Subject has had a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months of the screening visit. Subject has history of bleeding diathesis or coagulopathy, Type 1 diabetes, renal artery stenosis, valve disease, planned surgery or intervention in coming 6 months, allergy to listed drugs in protocol, is pregnant, or has peripheral disease precluding a 9F sheath introducer.

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 23, 2026